TEVA-LIOTHYRONINE TABLET
Country: Canada
Language: English
Source: Health Canada
Summary of Product characteristics
(SPC)
20-11-2019
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
LIOTHYRONINE (LIOTHYRONINE SODIUM)
Available from:
TEVA CANADA LIMITED
ATC code:
H03AA02
INN (International Name):
LIOTHYRONINE SODIUM
Dosage:
25MCG
Pharmaceutical form:
TABLET
Composition:
LIOTHYRONINE (LIOTHYRONINE SODIUM) 25MCG
Administration route:
ORAL
Units in package:
15G/50G
Prescription type:
Prescription
Therapeutic area:
THYROID AGENTS
Product summary:
Active ingredient group (AIG) number: 0102421002; AHFS:
Authorization status:
APPROVED
Authorization date:
2019-11-21
Summary of Product characteristics
_ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is
Read the complete document
